Psoriatic arthritis surgery could involve removing damaged tissue or bone or replacing a joint with severe damage. Learn more ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx (bimekizumab-bkzx) to include 3 new indications.

should be the target of all treatment strategies in psoriatic arthritis. All musculoskeletal and cutaneous manifestations of psoriatic disease need to be considered in treatment targets.

When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.

Otulfi is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active ...

Targeted therapies for PsA are effective for reducing the use of symptomatic treatments, sick leave, and rates of hospitalization.

Psoriasis (PSO) and psoriatic arthritis (PsA) are debilitating diseases that impact the life quality of ... 1 Injectable biologics (TNF-α, IL-12/IL-23, IL-17 and IL-23 inhibitors) are approved for the ...

Formycon AG (“Formycon”) and its commercialization partner Fresenius Kabi (“Fresenius”) jointly announced that the ...

Johnson & Johnson JNJ announced that it has discontinued the phase II field study, which evaluated the company’s ...